nzo mice
Recently Published Documents


TOTAL DOCUMENTS

37
(FIVE YEARS 10)

H-INDEX

13
(FIVE YEARS 1)

Author(s):  
Christiane Ott ◽  
Kathleen Pappritz ◽  
Niklas Hegemann ◽  
Cathleen John ◽  
Sarah Jeuthe ◽  
...  

Background Degenerative aortic valve (AoV) disease and resulting aortic stenosis are major clinical health problems. Murine models of valve disease are rare, resulting in a translational knowledge gap on underlying mechanisms, functional consequences, and potential therapies. Naïve New Zealand obese (NZO) mice were recently found to have a dramatic decline of left ventricular (LV) function at early age. Therefore, we aimed to identify the underlying cause of reduced LV function in NZO mice. Methods and Results Cardiac function and pulmonary hemodynamics of NZO and age‐matched C57BL/6J mice were monitored by serial echocardiographic examinations. AoVs in NZO mice demonstrated extensive thickening, asymmetric aortic leaflet formation, and cartilaginous transformation of the valvular stroma. Doppler echocardiography of the aorta revealed increased peak velocity profiles, holodiastolic flow reversal, and dilatation of the ascending aorta, consistent with aortic stenosis and regurgitation. Compensated LV hypertrophy deteriorated to decompensated LV failure and remodeling, as indicated by increased LV mass, interstitial fibrosis, and inflammatory cell infiltration. Elevated LV pressures in NZO mice were associated with lung congestion and cor pulmonale , evident as right ventricular dilatation, decreased right ventricular function, and increased mean right ventricular systolic pressure, indicative for the development of pulmonary hypertension and ultimately right ventricular failure. Conclusions NZO mice demonstrate as a novel murine model to spontaneously develop degenerative AoV disease, aortic stenosis, and the associated end organ damages of both ventricles and the lung. Closely mimicking the clinical scenario of degenerative AoV disease, the model may facilitate a better mechanistic understanding and testing of novel treatment strategies in degenerative AoV disease.


2021 ◽  
Vol 12 ◽  
Author(s):  
Lenise J. Kim ◽  
Mi-Kyung Shin ◽  
Huy Pho ◽  
Laszlo Otvos ◽  
Sergio Tufik ◽  
...  

BackgroundObesity can cause hypertension and exacerbates sleep-disordered breathing (SDB). Leptin is an adipocyte-produced hormone, which increases metabolic rate, suppresses appetite, modulates control of breathing, and increases blood pressure. Obese individuals with high circulating levels of leptin are resistant to metabolic and respiratory effects of leptin, but they appear to be sensitive to hypertensive effects of this hormone. Obesity-induced hypertension has been associated with hyperleptinemia. New Zealand obese (NZO) mice, a model of polygenic obesity, have high levels of circulating leptin and hypertension, and are prone to develop SDB, similarly to human obesity. We hypothesize that systemic leptin receptor blocker Allo-aca will treat hypertension in NZO mice without any effect on body weight, food intake, or breathing.MethodsMale NZO mice, 12–13 weeks of age, were treated with Allo-aca (n = 6) or a control peptide Gly11 (n = 12) for 8 consecutive days. Doses of 0.2 mg/kg were administered subcutaneously 2×/day, at 10 AM and 6 PM. Blood pressure was measured by telemetry for 48 h before and during peptide infusion. Ventilation was assessed by whole-body barometric plethysmography, control of breathing was examined by assessing the hypoxic ventilatory response (HVR), and polysomnography was performed during light-phase at baseline and during treatment. Heart rate variability analyses were performed to estimate the cardiac autonomic balance.ResultsSystemic leptin receptor blockade with Allo-aca did not affect body weight, body temperature, and food intake in NZO mice. Plasma levels of leptin did not change after the treatment with either Allo-aca or the control peptide Gy11. NZO mice were hypertensive at baseline and leptin receptor blocker Allo-aca significantly reduced the mean arterial pressure from 134.9 ± 3.1 to 124.9 ± 5.7 mmHg during the light phase (P < 0.05), whereas the control peptide had no effect. Leptin receptor blockade did not change the heart rate or cardiac autonomic balance. Allo-aca did not affect minute ventilation under normoxic or hypoxic conditions and HVR. Ventilation, apnea index, and oxygen desaturation during NREM and REM sleep did not change with leptin receptor blockade.ConclusionSystemic leptin receptor blockade attenuates hypertension in NZO mice, but does not exacerbate obesity and SDB. Thus, leptin receptor blockade represents a potential pharmacotherapy for obesity-associated hypertension.


2020 ◽  
Vol 8 (9) ◽  
Author(s):  
Katharina Grupe ◽  
Melissa Asuaje Pfeifer ◽  
Franziska Dannehl ◽  
Moritz Liebmann ◽  
Ingo Rustenbeck ◽  
...  

2019 ◽  
Author(s):  
M Stadion ◽  
C Quiclet ◽  
A Gässler ◽  
N Dittberner ◽  
TJ Schulz ◽  
...  

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 301-LB
Author(s):  
TERESA CASTAÑO-MARTINEZ ◽  
WENKE JONAS ◽  
DANIELA WEBER ◽  
CORNELIA WEIKERT ◽  
THOMAS LAEGER
Keyword(s):  

2019 ◽  
Author(s):  
T Castano Martinez ◽  
D Weber ◽  
C Weikert ◽  
A Schürmann ◽  
T Laeger

2019 ◽  
Author(s):  
M Stadion ◽  
C Quiclet ◽  
A Gässler ◽  
C Baumeier ◽  
TJ Schulz ◽  
...  

2019 ◽  
Vol 33 (6) ◽  
pp. 7092-7102 ◽  
Author(s):  
Teresa Castaño-Martinez ◽  
Fabian Schumacher ◽  
Silke Schumacher ◽  
Bastian Kochlik ◽  
Daniela Weber ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document